tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint reports inducement grants under NASDAQ listing rule
The FlyEyePoint reports inducement grants under NASDAQ listing rule
2d ago
EYPT
EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
PremiumRatings
EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
10d ago
EYPT
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
PremiumThe Fly
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
11d ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
1M ago
EYPT
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
PremiumRatings
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
1M ago
EYPT
Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD Therapy
PremiumRatingsBuy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD Therapy
1M ago
EYPT
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
Premium
The Fly
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
1M ago
EYPT
OCUL
EyePoint Pharmaceuticals: Strategic Positioning and Competitive Edge Reinforce Buy Rating
Premium
Ratings
EyePoint Pharmaceuticals: Strategic Positioning and Competitive Edge Reinforce Buy Rating
1M ago
EYPT
EyePoint Pharmaceuticals Announces Official Name Change
PremiumCompany Announcements
EyePoint Pharmaceuticals Announces Official Name Change
1M ago
8K
EYPT
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential
PremiumRatings
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential
2M ago
EYPT
PremiumRatings
EyePoint Pharmaceuticals: Positive DSMC Recommendations and Promising Clinical Trials Reinforce Buy Rating
2M ago
EYPT
PremiumCompany Announcements
EyePoint Pharmaceuticals Receives Positive Phase 3 Trial Update
2M ago
8K
EYPT
EyePoint announces DSMC completed review of Phase 3 trial for DURAVYU
PremiumThe FlyEyePoint announces DSMC completed review of Phase 3 trial for DURAVYU
2M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
Premium
The Fly
EyePoint reports inducement grants under NASDAQ listing rule
2M ago
EYPT
Premium
Ratings
Promising Outlook for EyePoint Pharmaceuticals with Duravyu’s Potential Impact on Wet AMD Treatment
2M ago
EYPT
EyePoint selloff brings buying opportunity, says Mizuho
PremiumThe Fly
EyePoint selloff brings buying opportunity, says Mizuho
2M ago
EYPT
PremiumCompany Announcements
EyePoint Pharmaceuticals Files $200M Stock Offering Prospectus
2M ago
8K
EYPT
PremiumRatings
EyePoint Pharmaceuticals: Strategic Advancements and Promising Developments Drive Buy Rating
2M ago
EYPT
PremiumCompany Announcements
EyePoint Pharma Advances DURAVYU in Retinal Disease Trials
2M ago
EYPT
PremiumCompany AnnouncementsEyePoint Pharma’s Earnings Call: Strategic Gains Amid Financial Hurdles
2M ago
EYPT
EyePoint reports Q3 EPS (85c), consensus (77c)
Premium
The Fly
EyePoint reports Q3 EPS (85c), consensus (77c)
2M ago
EYPT
EyePoint expects cash to fund operations into Q4 of 2027
Premium
The Fly
EyePoint expects cash to fund operations into Q4 of 2027
2M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >